Andres I respectfully accept your point of view but disagree that any rerate of significance can occur without consideration of share structure. Sure we have cash and sure trials should be positive for we shareholders but the greater benefit will always be achieved thru prudent capital management. Anyway no more arguing - we agree that IHL is a jewel - let's see how bright it shines
- Forums
- ASX - By Stock
- Ann: Clinical Progress on IHL-216A for TBI and CTE
Andres I respectfully accept your point of view but disagree...
-
- There are more pages in this discussion • 105 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)